Home › Trials › NCT06373055
Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Predicting chemotherapy response in bladder cancer patients

Official title: Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics

Run by Yonsei University · NCT06373055 · Data updated 2026-11-12

This study is trying to see if looking at the genes and molecules in bladder cancer patients can help figure out who will respond well to chemotherapy and who might need different treatments.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment250 (estimated)
SponsorYonsei University
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Seoul)
StatusRecruiting
StartedMay 1, 2024
Main results expectedNovember 2033
Study endsNovember 2033
Registry record updatedApril 18, 2024
Trial IDNCT06373055 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who are suspected of having bladder cancer and are scheduled for transurethral resection of bladder tumor.

Probably not a fit

Patients who do not agree to participate in the study or are considered vulnerable may not receive any benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify which patients with muscle-invasive bladder cancer will respond effectively to neoadjuvant chemotherapy. By analyzing the genetic and molecular profiles of patients scheduled for this treatment, the study seeks to differentiate between those who will benefit from chemotherapy and those who may require alternative treatments, such as radical cystectomy. The goal is to tailor treatment plans to improve patient outcomes and reduce unnecessary treatment toxicity and delays.

Why it matters

Potential benefit: If successful, this approach could lead to more personalized treatment plans, improving outcomes for bladder cancer patients.

How similar studies have gone: While this approach is innovative, similar studies have shown promise in predicting treatment responses in other cancers, suggesting potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion criteria:

* Suspicious of bladder cancer scheduled to have transurethral resection of bladder tumor
* Consent to the provision of their biospecimen.
* Willing to cooperate with this study and comply with the restrictions.
* Voluntarily signed the consent form for participation in the study.
* Age ≥18.

Exclusion criteria:

* Do not agree with this study.
* Vulnerable participants

Where it's running

  • Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea
    Seoul, South Korea     Recruiting

Study contacts

  • Principal investigator: Won Sik Ham — Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea
  • Study coordinator: Won Sik Ham
  • Email: uroham@yuhs.ac
  • Phone: 02-2228-2310

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Muscle-invasive Bladder Cancer 30Yonsei University 120
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.